IDEXX Laboratories Stock Jumps on Testing Products Demand, Higher Prices
1. IDEXX reported Q4 EPS of $2.62, exceeding forecasts significantly. 2. Revenue increased nearly 6% YoY, driven by strong demand in Companion Animal Group. 3. The company will launch a new canine lymphoma test in March. 4. IDEXX shares surged 10%, leading S&P 500 gainers following the earnings release. 5. Full-year EPS guidance is slightly below analyst expectations but remains robust.